INSULIN DELIVERY SYSTEM, Syringes , Insulin Pen, Insulin Pumps,

1. A REPORT ON INSULIN DELIVERY SYSTEM
Syringes
Latest syringes are smaller and have finer needles and special coatings that
work to make injecting as easy and painless as possible. When insulin injections
are done properly, most people discover they are relatively painless.
Insulin Pen
An insulin pen looks like a pen with a cartridge. Some pens use replaceable
cartridges of insulin; other pen models are totally disposable. A fine, short needle,
similar to the needle on an insulin syringe, is on the tip of the pen. Users turn a
dial to select the desired dose of insulin and press a plunger on the end to deliver
the insulin just under the skin.
Insulin Pumps
These high technology products are miniature, computerized pumps. They are
about the size of a beeper, weigh about 3 ounces, and deliver insulin through a
flexible plastic tube attached to the body. The pump mimics a healthy pancreas
by offering insulin delivery in two ways. First, it provides a rhythmic, continuous
drip of insulin, which is known as the basal dose, all day long. Second, the pump
allows you to add an additional amount of insulin when you eat. This extra dose
is called a bolus. You request your bolus with a simple push of button. You
usually determine the size of the bolus by estimating the amount of carbohydrate
youwillbeeating.
Inhaled Insulin
Inhaled System of Insulin delivery is the latest Product offering several
advantages over the other conventional Systems
Business Opportunity Overview
Number of Diabetic Patients is on the increase & Insulin Market in India is placed
around INR 250 Crores with about 30 % growth rate. The Inject able Insulin
Market is comprised of products such as Insulin Syringes, insulin Pen , Insulin
Pumps & Jet Injectors Then there are Inhaled Insulin products, Oral Insulin
Markets, Nasal Insulin delivery technology, Transdermal Insulin Delivery, Rectal
Insulin Delivery, Ultrasound Insulin delivery, Iontophoresis Insulin Delivery
Technology, Electro oration Insulin Delivery Technology and so on The products
are Highly Technology Oriented and there are very few players in the world
Market. Indian Market is served by Imports & therefore priced high. There are
attempts to start manufacturing these products in the country & therefore, the
Insulin Delivery Systems market in India is considered to be very bright.

2. LIST OF PROSPECTIVE BUYERS FOR INSULIN DELIVERY SYSTEM IN INDIA
INSULIN DELIVERY SYSTEM IN INDIA
There are seven brands of human insulin available in India. These include both
Indian and foreign brands. Insulin is available in vial form in different strengths
ranging from 40 iu/ml to100 iu/ml. In November 2004, Biocon, a Bangalore
based Indian company, launched a new generation of bio-insulin called Insugen.
In August 2005, Eli Lilly India launched its insulin analog under the brand name
of Humalog Mix 25-50. Indian companies like Wockhardt, Shantha Biotechnics
and Intas Pharmaceutical manufacture erythropoietin. Several other Indian
companies have licensing agreements with the multi-national companies (MNCs)
to market recombinant erythropoietin. Janssen Cilag CRF a division of Johnson
& Johnson was amongst the first companies to successfully launch a
biotechnology drug in India under the brand name Eprex. Hindustan Antibiotics
has tied up with a U.S. company Elanex Pharmaceutical to market their product
under the brand name Hemax.
Recombinant Brand Company
Human Insulin
Huminsulin Eli Lily and Company India
Insugen Biocon
NovoMix39 and NovoRapid Novo Nordisk
Reconsulin Shreyas Life Sciences
Wosulin Wockhardt
Streptokinase
Indikinase Bharat Biotech
Shankinase Shantha Biotechnics
STPase Cadila Pharmaceuticals
Erythropoietin
Ceriton Ranbaxy
Epofit and Erykine Intas Pharma
Eprex J& J
Hemax Hindustan Antibiotics
LG Espogen LG Chemicals
Shanpoietin Shantha Biotechnics
Vintor for Nephrology/Epofer for Emcure
Haematinics
Wepox Wockhardt
Zyrop Zdyus Biogen
Hepatitis B Vaccine
Bevac Biological E
Biovac B Wockhardt
Engenix-B GlaxoSmithKline India
Enivac HB Panacea Biotec

3. Gene Vac-B Serum Institute of India
LGEuvax B Inj LG Chemicals
Revac B Bharat Biotech
Shanvac B Shantha Biotechnics
Human Growth Hormone
Humatrope Eli Lilly India
LG Eutropin Inj LG Chemicals
Norditropin, NordiLet Novo Nordisk
Saizen Serum Institute of India
G-CSF
Emgrast Emcure
Grastim Dr. Reddy’s Labs
Neukine Intas Pharma
Interferon alpha 2a
LG Intermax alpha Inj LG Chemicals
Interferon alpha 2b
Intron A Fulford India (Schering
Plough)
Markferon Glenmark Labs
Shanferon Shantha Biotechnics
Zaveinex Zdyus Biogen
Interferon beta 1a
Avonex Nicholas Piramal- Biogen
Blood Factor VIII
FSH Gonal-F Serum Institute of India
Ltd.
LG Follimon Inj LG Chemicals
Tissue Plasminogen Activator German Remedies
Alpha Drotrecogin
Xigris Eli Lily and Company
(India)

4. Indian Disease Burden Estimations
The growing population, change in disease patterns, and demand for new
medicines to combat these diseases are leading to increased demand for bio
drug, vaccines and diagnostics products. The below table provides the
estimated cases of diseases in 100,000.
Disease/Health Condition 2000-05 2015
Communicable Diseases, Maternal & Prenatal Conditions
Tuberculosis 85 NA
HIV/AIDS 51 190
Diarrheal Disease episodes/yr 760 880
Malaria and other vector borne 20.37 NA
conditions
Leprosy 3.67 Expected to be
eliminated
MR/1000 births 63 53.14
Otitis Media 3.57 4.18
Maternal Mortality/100000 births 440 NA
Non-Communicable Conditions
Cancers 8.07 9.99
Diabetes 310 460
Mental Health 650 800
Blindness 141.07 129.96
Cardiovascular Diseases 290 640
COPD and Asthma 290 640
Though non-injectable forms of insulin are more costly per dose than their
injectable counterparts, demand is expected to soar in coming years, even in
price-sensitive countries like India. “If Pfizer was the only company, then price
would be an issue. But with so many competitors, pharma companies cannot out-
price themselves,” says Mr. Mattoo.
Though non-injectable forms of insulin are more costly per dose than their
injectable counterparts, demand is expected to soar in coming years, even in
price-sensitive countries like India. “If Pfizer was the only company, then price
would be an issue. But with so many competitors, pharma companies cannot out-
price themselves,” says Mr. Mattoo.
Key Suppliers
The major suppliers of biotechnology products include U.S., European and Indian
companies. Some of the Indian companies manufacturing healthcare
biotechnology products include Bharat Biotech International, Bharat

5. Immunological and Biological, Bharat Serum, Biocon, Dr Reddy’s, Haffkine Bio-
Pharma, Indian Immunological, Krebs Biochemical, Panacea Biotec, Serum
Institute of India, Shantha Biotechnics, Wockhardt, Ranbaxy Laboratories,
Organon India, Kee Pharma, Emcure Pharmaceuticals, Glenmark Labs, Lupin
Labs, Nicholas Piramal, Intas Pharma, Hindustan Antibiotics and Shreyas Life
Sciences.Foreign companies in India include Eli Lilly, Novadisk, Johnson &
Johnson, Fulford India, Wyeth Lederle, Glaxo SmithKline, Aventis Pharma, Pifzer
and LG Chemical
Distributors in India for insulin injection system
1. Shreya Life Sciences Pvt. Ltd. (www.shreya.co.in)
In August, 2007 Generex entered into a Master Product Licensing & Distribution
Agreement with Shreya Life Sciences, a leading Indian-based pharmaceutical
company. Shreya is the fourth largest distributor of insulin in the Indian market
and has interests in both pharmaceutical and biopharmaceutical products in key
therapeutic segments including cardiology, neuropathy, and diabetes.
India has a significant and growing number of people with diabetes. According to
the Diabetes Atlas 2007, there are approximately 40.8 million diagnosed patients
with diabetes in India. There are also an estimated 35.9 million people who have
pre-diabetic conditions which, if not properly treated and managed, could lead to
full-blown diabetes. Generex believes that early intervention with insulin therapy
could delay the onset and progression of diabetes and its numerous
complications. Generex Oral-lyn, as a convenient and pain-free alternative to
insulin injections, could encourage prandial insulin therapy among those patients
who presently avoid injections.
"We are pleased to anticipate the commercialization of our flagship product in a
major market like India and the attendant revenue," said Anna Gluskin,
Generex's President & Chief Executive Officer. "We are optimistic about the
establishment of a new treatment paradigm for diabetes and pre-diabetic
conditions in India and other countries where we are now pursuing approvals.
We look forward to working with Shreya to expand the market in India in order to
capture a wider patient population." Generex Oral-lyn is presently in Phase III
clinical trials at several sites around the world.
About Generex
Generex is engaged in the research, development, and commercialization of
drug delivery systems and technologies. Generex has developed a proprietary
platform technology for the delivery of drugs into the human body through the
oral cavity (with no deposit in the lungs). The Company's proprietary liquid
formulations allow drugs typically administered by injection to be absorbed into
the body by the lining of the inner mouth using the Company's proprietary
RapidMist(tm) device. The Company's flagship product, oral insulin (Generex
Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients
with Type-1 and Type-2 diabetes and which was approved for sale in India in

6. October 2007, is in various stages of clinical development around the world. For
more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time
by Generex representatives concerning the same subject matter may contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by introductory
words such as "expects," "plans," "intends," "believes," "will," "estimates,"
"forecasts," "projects" or words of similar meaning, and by the fact that they do
not relate strictly to historical or current facts. Forward-looking statements
frequently are used in discussing potential product applications, potential
collaborations, product development activities, clinical studies, regulatory
submissions and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements, including
inaccurate assumptions and a broad variety of risks and uncertainties, some of
which are known and others of which are not. Known risks and uncertainties
include those identified from time to time in the reports filed by Generex with the
Securities and Exchange Commission, which should be considered together with
any forward-looking statement. No forward-looking statement is a guarantee of
future results or events, and one should avoid placing undue reliance on such
statements. Generex undertakes no obligation to update publicly any forward-
looking statements, whether as a result of new information, future events or
otherwise. Generex cannot be sure when or if it will be permitted by regulatory
agencies to undertake additional clinical trials or to commence any particular
phase of clinical trials. Because of this, statements regarding the expected timing
of clinical trials cannot be regarded as actual predictions of when Generex will
obtain regulatory approval for any "phase" of clinical trials. Generex claims the
protection of the safe harbor for forward-looking statements that is contained in
the Private Securities Litigation Reform Act.
SHERYA LIFE SCIENCE PRIVATE LIMITED
Company Profile
Tablets, Capsules, Injections, Cream, Syrup, Solution, Ophthalmic Solution
Relevant Chemicals, Pharmaceuticals And Medical Equipment
Categories :
Product Pharmaceutical Formulations
Profile :
Address : shreya house, 301/a, Pereira hill road,, andheri (e),,
MUMBAI 400099
Telephone :
Fax : 91-022-6939222

7. 3. MANTHAN.INC
WE ARE PHARMACEUTICAL DISTRIBUTORS DEALING IN BRANDED
FORMULATIONS AS WELL AS GENERIC MEDICINES. We ARE INTRSTED IN
EXPORT OF Indian PHARMA PRODUCTS. We CAN PROFESSIONALLY
WORK AS AN INDENTING PARTNER FROM India. We ARE AUTHORISED
AGENT / SERVICE PROVIDER FOR MEDISENSE ABBOTT'S OPTIUM
GLUCOMETER & STRIPS (U. S. A) AS WELL AS INSULIN RANGE OF
INJECTIONS OF NOVO NORDISK IN MUMBAI, India.
WE ARE CONSIGNEE AGENT OF WELL KNOWN INTERNATIONAL
PRODUCTS OF VENOUS SHUNT (NEUROLOGY) , PENILE PROSTHESIS ...
Company Profile
Basic Information
Company Name: MANTHAN INC.
Business Type: Trading Company, Distributor/Wholesaler
Medicines, Surgicals, Venous Shunt, Ortho Implants,
Product/Service:
Penile Prosthiasis
Trade & Market
HOSPITALS/GOVT.INSTITUTIONS/CORPORATE
Main Customers:
CO/DOCTORS
Total Annual Sales
Below US$1 Million
Volume:
Export Percentage: 1% - 10%
Total Annual
Below US$1 Million
Purchase Volume:
3, POOJA SURGICALS
We introduce with our selves, i m bhupen patel, my company established in 2001.
Already i export in various country " Africa, Nigeria, malawi, Zambia, angola,
seira leon, angola, Congo, netherland, trinidad tobage, lebenon, South Africa,
namibia, etc. . I have ISO, ce & gmp certified product. If u any confusion so u can

8. contact directly Offering to sell transfusion set, I. v set, blood transfusion set,
infusion set, scalp vein set, blood administration set, urine bag, cord clamp-two
type
Company Profile
Basic Information
Company Name: Pooja Surgicals
Business Type: Manufacturer, Distributor/Wholesaler
Surgical Disposable, Medical Disposable, Surgical
Product/Service: Equipment, Surgical Dressing, Medical Equipment,
Hospital Item
Number of
51 - 100 People
Employees:
Trade & Market
North America
South America
Eastern Europe
Southeast Asia
Main Markets:
Africa
Oceania
Mid East
Western Europe
Total Annual Sales
Below US$1 Million
Volume:
Export Percentage: 41% - 50%
Total Annual
US$2.5 Million - US$5 Million
Purchase Volume:
Factory Information
Factory Size1,000-3,000 square meters

9. (Sq.meters):
QA/QC: In House
Number of Production
4
Lines:
Number of R&D Staff: 61 - 70 People
Number of QC Staff: 21 - 30 People
Management
ISO 9000/9001/9004/19011: 2000
Certification:
Contract
OEM Service Offered
Manufacturing:
4.HI-GI LABS PVT LIMITED
Our Company Hi-Gi Labs Pvt Ltd., started with an innovative idea of taking the
Healthcare products to the doorstep of the patients. It quickly grew from a
handful of customers to 10's of 1000's of patients spread in various cities. The
high quality and low cost products sent to the patients on subscription basis not
only provide convenience to the patients but also offer them great savings.
Today, after successfully catering to the Diabetic patients with
door-delivery of Insulin syringes
Company Profile
Basic Information
Company Name: HI-GI Labs Pvt Ltd
Business Type: Distributor/Wholesaler
Product/Service: Post mastectomy breast forms and mastectomy bras
Number of
11 - 50 People
Employees:
Trade & Market
North America
Main Markets:
South America

10. Western Europe
Eastern Europe
Eastern Asia
Southeast Asia
Mid East
Africa
Oceania
Pharmaceutical Associations In India
Pharmaceutical Associations In India
Email
SNo Name Address Address/Website
Indian Drug 102-B, Poonam mailto:E-Mail:idma
Manufacturers Chambers, A-
Association Wing, Dr.
A .B.Road, Worli
Mumbai-400018
Tel : 22- @giasbmol,
4974308/4944624
Fax : 22-4950723 vsnl.net.in http://
www.idma-assn.org/
1

11. Organisation of oppi@bom3.vsnl.net.in
Pharmaceutical
Producers of
India Cook's Building,
324,
Dr.Dadabhay
Naroji Road,
Mumbai-400001
Tel : 2045509,
2044518
Fax : 022-
2 2044705
Bulk Drug
Manufacturers
Association
A-24, 2nd floor,
View Towers,
Lakadi Ka Pul,
Hyderabad-
500004
Tel :
3 3322142/3316328 .
26, Bhargav
Lane, Vivil Line,
Nityanand Marg,
Delhi -54
Tel : 2919140,
2918567
All India Small
Scale Fax :
Pharmaceutical 2524302,2937857
Manufacturers
4 Association .

12. Federation ficci.bisnet
House, Tansen
Marg, New Delhi-
110001
Tel : 3738760-70 @gems.vsnl.net.in
Federation of Fax:91-11-
Indian 3320714,3721504
Chambers of
Commerce and
5 Industry
Confederation 23, Industrial td@co.cii.ernet.in
of Indian Area, Lodi Estate,
Industry New Delhi - 110
003
Tel : 4621874, http://www.indian
4629994-7
Fax: 4633168, industry.com/
4626149
6
Prospective Buyers
Most of the bio drugs and diagnostic products are for the government and private
sector hospitals and patients. The second group of buyers of biotechnology
products and bio molecules are the research institutes and pharmaceutical
companies. The emerging trend of corporate players establishing diagnostic
centers in small towns and rural areas will provide opportunities for the import of
automated systems and imported reagents. Currently, there are only a few large
national players in diagnostics care segment including SRL Ranbaxy, Max
Healthcare, Dr. Lal’s Laboratory, Metropolis, Thyrocare, Fortis Healthcare and
Apollo Clinics. The large private hospitals are upgrading their facilities and/or
adding new facilities.

13. MARKET POTENTIAL OF INSULIN DELIVERY SYSTEM IN INDIA:
Summary
The size of the Indian biotechnology industry is estimated at $1.3 billion. This
includes bio-healthcare, bio-agriculture, bio-industrial, bio-informatics, and
contract and clinical research markets. Of the total market, healthcare
biotechnology products account for 38 percent. The growing population, demand
for quality diagnostics products and innovative drugs to combat diseases are
leading to increased demand for biotechnology drugs and products. New types
of diseases and demand for improved drugs are also leading to greater research
and development (R&D) activities
Number of Diabetic Patients are on the increase & Insulin Market in India is
placed around INR 250 Crores with about 30 % growth rate. The Inject able
Insulin Market is comprised of products such as Insulin Syringes, insulin Pen ,
Insulin Pumps & Jet Injectors Then there are Inhaled Insulin products, Oral
Insulin Markets, Nasal Insulin delivery technology, Transdermal Insulin Delivery,
Rectal Insulin Delivery, Ultrasound Insulin delivery, Iontophoresis Insulin Delivery
Technology, Electro oration Insulin Delivery Technology and so on The products
are Highly Technology Oriented and there are very few players in the world
Market. Indian Market is served by Imports & therefore priced high. There are
attempts to start manufacturing these products in the country & therefore, the
Insulin Delivery Systems market in India is considered to be very bright. India has
a significant and growing number of people with diabetes. According to the
Diabetes Atlas 2007, there are approximately 40.8 million diagnosed patients
with diabetes in India. There are also an estimated 35.9 million people who have
pre-diabetic conditions which, if not properly treated and managed, could lead to
full-blown diabetes. Generex believes that early intervention with insulin therapy
could delay the onset and progression of diabetes and its numerous
complications. Generex Oral-lyn, as a convenient and pain-free alternative to
insulin injections, could encourage prandial insulin therapy among those patients
who presently avoid injections
Market Trends
In line with the global markets the Indian market for recombinant products is showing
considerable growth. The Department of Biotechnology (DBT) has estimated the Indian market
for recombinant therapeutics products at $90 million, which is growing at a rate of 30 percent
per annum.

14. Product Market Size Growth Rate
Erythropoietin $16.6 million 20 percent
G-CSF $6 million 25-30 percent
FSH Market $6 million 20 percent
Interferon $12-13 million 30-40 percent
Insulin $55 million 40 percent
Hepatitis B Vaccine $22 million NA
Streptokinase $17 million 25 percent
In 2030, the number of diabetics is expected to reach 80 million in India
According to WHO statistics, the number of people with diabetes in India is set to
rise from 40.8 million today to approx.75 million in the year 2025. In less than 20
years the number of diabetics in India will be equivalent to the whole population
of Germany today. In 2005, the Indian insulin market was worth approx. CHF 88
million; this figure is likely to grow toCHF 121 million by 2010.
Ypsomed sees great potential for pen needles and pen systems in India
In India 85% of all insulin is administered with normal syringes and just 15%
using cartridges and pen systems. The currently low level of penetration of
insulin pen systems will rise significantly in the future as sales of insulin in pen
systems are now growing by some 35% annually. “The diabetes market will grow
strongly in India in the coming years and holdout very great potential for
Ypsomed, both for pen needles and also for insulin pens and new pen systems
for liquid
Pharmaceuticals,” comments CEO Richard Fritschi.
Pen needles are a major source of earnings for Ypsomed with further growth
potential
The pen needles developed and manufactured by Ypsomed with the patented
click-on mechanism fit all pen systems available today for insulin, growth
hormones or other therapies. Ypsomed’s pen needles are currently distributed in
around30 countries, either through Ypsomed’s own subsidiary companies or via
local distributors. Ypsomed’s pen needle business has grown in recent years by
an annual average of around 25% and holds out further growth potential. Senior
Vice President of Marketing & Sales, Detlef Jantos: “Ypsomed’s click-on pen
needles have a number of advantages overthe competition and are very popular
with pen users. To enable future demand to be met, Ypsomed will be expanding
itspen needle production capacity considerably and will invest in the next two
years a total of more than CHF 35 million at theSolothurn site.” Ypsomed has
also developed a new safety pen needle which is due to be launched in 2009 to
enable pensystems to be used in the public healthcare sector i.e. in hospitals and
nursing .

15. IMPORTING THE PRODUCT AND GOVERNMENT POLICIES IN INDIA:
Globally, 240 recombinant therapeutic products have been approved. The Government of India
(GOI) has approved only 14 of these products for sale in India. These include human insulin,
blood factor VIII, erythropoietin, granulocyte colony stimulating factor (G-CSF), alpha
interferon, interferon b, GMCSF, streptokinase, basiliximab, follicle stimulating hormone
(FSH), and hepatitis-B. Of these 14 GOI approved recombinant drugs, 7 are being locally
manufactured while the rest are being imported. Sun Pharmaceutical and Torrent
Pharmaceutical are into contract manufacturing of recombinant products for Eli Lilly and Novo
Nordisk. Though several Indian companies are engaged in research and development of
recombinant products, presently only 6 Indian companies are manufacturing them while 16
companies are importing and selling recombinant products in India.
Biotech Clusters
The central and state governments have been taking many initiatives to support
the biotechnology industry through development of biotechnology parks, policy
initiatives, and tax incentives. Governments are working towards developing
cities for knowledge-based sectors like biotechnology, medical biosciences, and
life sciences. It is estimated that India will have at least 20 biotech parks in the
next few years. Currently four cities – Chennai, Hyderabad, Lucknow and Pune
– have taken the lead in developing biotechnology-dedicated parks. Other states
that have announced plans to develop biotechnology parks include Karnataka,
Kerala, Tamil Nadu, Gujarat, Chandigarh, Haryana, Himachal Pradesh, Madhya
Pradesh, Punjab, Rajasthan, Uttar Pradesh and Uttaranchal, Orissa and West
Bengal.
The following are the existing biotechnology parks: The Shapoorji Pallonji
Biotech Park in Andhra Pradesh is a public-private partnership between the state
Government and Shapoorji Pallonji Incorporated. 20 companies both Indian and
foreign have established their units in this Park, making an investment of $85-90
million. Sigma Aldrich from U.S. and Altanta AG from Germany are planning to
establish facilities in this Park, while Randox Laboratories from U.K. is
establishing a diagnostic kits manufacturing unit in Bangalore.
Another park in Andhra Pradesh is the ICICI Knowledge Park. This park is
focused on
facilitating business-driven research and development. The park is spread over
200 acres and about 13-15 companies, both Indian and foreign, are currently
operating there.

16. Indian government rules and regulation for pharmaceutical firm
The drug and pharmaceutical industry in the country today faces new challenges
on account of liberalization of the Indian economy, the globalization of the world
economy and on account of new obligations undertaken by India under the WTO
Agreements. These challenges require a change in emphasis in the current
pharmaceutical policy and the need for new initiatives beyond those enumerated
in the Drug Policy 1986, as modified in 1994, so that policy inputs are directed
more towards promoting accelerated growth of the pharmaceutical industry and
towards making it more internationally competitive. The process of liberalization
set in motion in 19901, has considerably reduced the scope of industrial licensing
and demolished many non-tariff barriers to imports. Some of the steps taken are:
Abolition of industrial licensing for manufacture of all drugs and pharmaceuticals
except for bulk drugs produced by the use of recombinant DNA technology, bulk
drugs requiring in-vivo use of nucleic acids, and specific cell tissue targeted
formulation. Reservation of 5 drugs for manufacture by the public sector only was
abolished in Feb.1999, thus opening them up for manufacture by the private
sector also. Foreign investment through automatic route was raised from 51% to
74% in March, 2000 and the same has been raised to 100%.
Drugs and pharmaceuticals manufacturing units in the public sector are being
allowed to face competition including competition from imports. Wherever
possible, these units are being privatized.
Introduction of the Patents (Second Amendment) bill in the Parliament. It, inter-
alia, provides for the extension in the life of a patent to 20 years.
The main objectives of this policy are:-
a. Ensuring abundant availability at reasonable prices within the country of
good quality essential pharmaceuticals of mass consumption.
b. Strengthening the indigenous capability for cost effective quality
production and exports of pharmaceuticals by reducing barriers to trade in
the pharmaceutical sector.
c. Strengthening the system of quality control over drug and pharmaceutical
production and distribution to make quality an essential attribute of the
Indian pharmaceutical industry and promoting rational use of
pharmaceuticals.
d. Encouraging R&D in the pharmaceutical sector in a manner compatible
with the country's needs and with particular focus on diseases endemic or
relevant to India by creating an environment conducive to channelising a
higher level of investment into R&D in pharmaceuticals in India.
e. Creating an incentive framework for the pharmaceutical industry which
promotes new investment into pharmaceutical industry and encourages
the introduction of new technologies and new drugs.

17. Industrial Licensing
Industrial licensing for all bulk drugs cleared by Drug Controller General (India),
all their intermediates and formulations will be abolished, subject to stipulations
laid down from time to time in the Industrial Policy, except in the cases of
 bulk drugs produced by the use of recombinant DNA technology,
 bulk drugs requiring in-vivo use of nucleic acids as the active principles, a
 specific cell/tissue targeted formulations
Foreign Investment
Foreign investment unto 100% will be permitted, subject to stipulations laid down
from time to time in the Industrial Policy, through the automatic route in the case
of all bulk drugs cleared by Drug Controller General (India), all their intermediates
and formulations, except those, referred to in Para 12.I above, kept under
industrial licensing
Imports
Imports of drugs and pharmaceuticals will be as per EXIM policy in force. A
centralized system of registration will be introduced under the Drugs and
Cosmetics Act and Rules made there under. Ministry of Health and Family
Welfare will enforce strict regulatory processes for import of bulk drugs and
formulations
Pricing of Formulations
 For Scheduled formulations, prices shall be determined as per the present
practice. The time frame for granting price approvals will be two months
from the date of the receipt of the complete prescribed information.
 The present stipulation that a manufacturer, distributor or wholesaler shall
sell a formulation to a retailer, unless otherwise permitted under the
provisions of Drugs (Prices Control) Order or any other order made there
under, at a price equal to the retail price, as specified by an order or
notified by the Government, (excluding excise duty, if any) minus sixteen
percent thereof in case of Scheduled drugs, will continue.
 The present provision of limiting profitability of pharmaceutical companies,
as per the Third Schedule of the present Drugs (Prices Control) Order,
1995, would be done away with. However, if necessary so to do in public
interest, price of any formulation including a non-Scheduled formulation
would be fixed or revised by the Government

18. Promotional strategy to be followed
1) Targeting the various hospitals within the country which includes: Apollo
group. Wockhart., Escort hospital etc
2) Going for the TV commercial and also showing various close associations
by showing the approval of drug my the health ministry of India& various
other medical associations
3) Running various diabetics awareness by tying up with various news
channels and local NGO like rotary club which show we care our customer
as well as to gain top of the mind awareness slot in the mind of customers.
4) Going for a celebrity, who might be suffering from diabetes, show how our
product had help him/her to control the disease and same thing can work
for you to.
5) Going for various print media. Like newspaper again we help in the
awareness about the product.
6) Tying up with various distributors like Sherya science private limited so as
to make the availability as well as the reach of the product to be as far as
possible within the country.
7) High ring various medical representatives (MR) and send them to various
doctors at different places within the country so as to again make product
getting familiar with the doctor, hence also can be recommended to the
various patient arriving for the treatment.
8) Running promotional activities two to three times a year within the country.